Association between Body Composition and Peripheral Neurotoxicity in Cancer Patients from North China Taking Nab-Paclitaxel

References

• Hopkins JJ, Sawyer MB. A review of body composition and pharmacokinetics in oncology. Expert Rev Clin Pharmacol. 2017;10(9):947–56. doi: 10.1080/17512433.2017.1347503. Epub 2017 Jul 5. PMID: 28649898.
   PubMed Web of Science ®Google Scholar
• Hu LY, Mi WL, Wu GC, Wang YQ, Mao-Ying QL. Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms. Curr Neuropharmacol. 2019;17(2):184–96. doi: 10.2174/1570159X15666170915143217.
   PubMed Web of Science ®Google Scholar
• Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan, M, C. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin. 2013;63(6):419–37. doi: 10.3322/caac.21204.
   PubMed Web of Science ®Google Scholar
• Bernhardson BM, Tishelman C, Rutqvist LE. Chemosensory changes experienced by patients undergoing cancer chemotherapy: A qualitative interview study. J Pain Symptom Manag. 2007;34(4):403–12. doi: 10.1016/j.jpainsymman.2006.12.010.
   PubMed Web of Science ®Google Scholar
• Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol. 2016;73(7):860–6. doi: 10.1001/jamaneurol.2016.0383.
   PubMed Web of Science ®Google Scholar
• Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 May;19(2):171–7. doi: 10.1023/a:1010639207.
   PubMed Web of Science ®Google Scholar
• Shuter B, Aslani A. Body surface area: Du Bois and Du Bois revisited. Eur J Appl Physiol. 2000;82(3):250–4. doi: 10.1007/s004210050679. PMID: 10929220.
   PubMed Web of Science ®Google Scholar
• Von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle. 2010;1(2):129–33. doi: 10.1007/s13539-010-0014-2. Epub 2010 Dec 17. PMID: 21475695; PMCID: PMC3060646.
   PubMed Web of Science ®Google Scholar
• Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle. 2020;11(2):366–80. doi: 10.1002/jcsm.12525. Epub 2020 Jan 8. PMID: 31916411; PMCID: PMC7113510.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. doi: 10.1016/S1470-2045(10)70218-7.
   PubMed Web of Science ®Google Scholar
• Jafri SH, Previgliano C, Khandelwal K, Shi R. Cachexia index in advanced non-small-cell lung cancer patients. Clin Med Insights Oncol. 2015;9;9:87–93. doi: 10.4137/CMO.S30891.
   PubMedGoogle Scholar
• Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, et al. Prognostic factors for risk stratification of patients with recurrent or metastatic pancreatic adenocarcinoma who were treated with gemcitabine-based chemotherapy. Cancer Res Treat. 2016;48(4):1264–73. doi: 10.4143/crt.2015.250.
   PubMed Web of Science ®Google Scholar
• Rinninella E, Cintoni M, Raoul P, Pozzo C, Strippoli A, Bria E, Tortora G, Gasbarrini A, Mele MC. Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: A systematic review and meta-analysis. Clin Nutr. 2020;39(7):2045–54. doi: 10.1016/j.clnu.2019.10.021.
   PubMed Web of Science ®Google Scholar
• Yabusaki N, Fujii T, Yamada S, Suzuki K, Sugimoto H, Kanda M, Nakayama G, Koike M, Fujiwara M, Kodera Y. Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection. Int J Surg. 2016;30:136–42. doi: 10.1016/j.ijsu.2016.04.049.
   PubMed Web of Science ®Google Scholar
• Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F. Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma. J Urol. 2016;195(1):26–32. doi: 10.1016/j.juro.2015.08.071.
   PubMed Web of Science ®Google Scholar
• Malietzis G, Currie AC, Athanasiou T, Johns N, Anyamene N, Glynne-Jones R, Kennedy RH, Fearon KC, Jenkins JT. Influence of body composition profile on outcomes following colorectal cancer surgery. Br J Surg. 2016;103(5):572–80. doi: 10.1002/bjs.10075.
   PubMed Web of Science ®Google Scholar
• Srikanthan P, Karlamangla AS. Muscle mass index as a predictor of longevity in older adults. Am J Med. 2014;127(6):547–53. doi: 10.1016/j.amjmed.2014.02.007.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–803. doi: 10.1200/JCO.2005.04.937.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055–62. doi: 10.1200/JCO.2011.39.5848.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. doi: 10.1056/NEJMoa1304369.
   PubMed Web of Science ®Google Scholar
• Wong AL, Seng KY, Ong EM, Wang LZ, Oscar H, Cordero MT, Copones R, Fan L, Tan SH, Goh BC, et al. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat. 2014;144(1):143–52. doi: 10.1007/s10549-014-2843-8.
   PubMed Web of Science ®Google Scholar
• Iritani S, Imai K, Takai K, Hanai T, Ideta T, Miyazaki T, Suetsugu A, Shiraki M, Shimizu M, Moriwaki H. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol. 2015;50(3):323–32. doi: 10.1007/s00535-014-0964-9.
   PubMed Web of Science ®Google Scholar
• Hanping S, Wei L, Gongyan C, Junwen O. Tumor cachexia19 Panjiayuan Nanli. Beijing: People’s Health Publishing House, 2015.
   Google Scholar
• Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997–1006. doi: 10.1139/H08-075.
   PubMed Web of Science ®Google Scholar
• Park SE, Choi JH, Park JY, Kim BJ, Kim JG, Kim JW, Park JM, Chi KC, Hwang IG. Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer. Sci Rep. 2020;10(1):17683. doi: 10.1038/s41598-020-74765-8.
   PubMed Web of Science ®Google Scholar
• Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017;81(6):772–81. doi: 10.1002/ana.24951.
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47. doi: 10.1200/JCO.2012.45.2722.
   PubMed Web of Science ®Google Scholar
• Pin F, Couch ME, Bonetto A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr Opin Support Palliat Care. 2018;12(4):420–6. doi: 10.1097/SPC.0000000000000382.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15(8):2920–6. doi: 10.1158/1078-0432.CCR-08-2242.
   PubMed Web of Science ®Google Scholar
• Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, Mollevi C, Senesse P. Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med. 2016;5(4):607–16. doi: 10.1002/cam4.621.
   PubMed Web of Science ®Google Scholar
• Sjøblom B, Grønberg BH, Benth JŠ, Baracos VE, Fløtten Ø, Hjermstad MJ, Aass N, Jordhøy M. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer. 2015;90(1):85–91.
   PubMed Web of Science ®Google Scholar
• Youn S, Chen A, Ha V, Chambers C, Eurich DT, McCall M, Sawyer MB. An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel. Clin Nutr. 2021;40(8):4888–92. doi: 10.1016/j.clnu.2021.06.026.
   PubMed Web of Science ®Google Scholar
• Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, Benbow JM, Muss HB. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res. 2017;23(3):658–65. doi: 10.1158/1078-0432.CCR-16-0940.
   PubMed Web of Science ®Google Scholar
• Freckelton J, Croagh D, Holt DQ, Fox A, Wong R, Lee M, Moore GT. Body composition adjusted dosing of gemcitabine-nab-paclitaxel in pancreatic cancer does not predict toxicity compared to body surface area dosing. Nutr Cancer. 2019;71(4):624–8. doi: 10.1080/01635581.2018.1542011.
   PubMed Web of Science ®Google Scholar
• Athauda A, Nankivell M, Langley RE, Alderson D, Allum W, Grabsch HI, Starling N, Chau I, Cunningham D. Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03). Eur J Cancer. 2020;137:45–56. doi: 10.1016/j.ejca.2020.06.005.
   PubMed Web of Science ®Google Scholar
• Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, Latko E, Taieb J. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014;66(4):583–9.
   PubMed Web of Science ®Google Scholar
• Kurita Y, Kobayashi N, Tokuhisa M, Goto A, Kubota K, Endo I, Nakajima A, Ichikawa Y. Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy. Pancreatology. 2019;19(1):127–35. doi: 10.1016/j.pan.2018.11.001.
   PubMed Web of Science ®Google Scholar
• Dijksterhuis WPM, Pruijt MJ, van der Woude SO, Klaassen R, Kurk SA, van Oijen MGH, van Laarhoven HWM. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy. J Cachexia Sarcopenia Muscle. 2019;10(1):199–206. doi: 10.1002/jcsm.12371.
   PubMed Web of Science ®Google Scholar